PARIS - Cerep SA reported encouraging, but mixed, results from a proof-of-concept Phase I/II trial of a cancer drug developed by its subsidiary, Cerenis, which is being tested in refractory or relapsing acute myeloid leukemia (AML). (BioWorld International)

PARIS - Cerep SA reported encouraging, but mixed, results from a proof-of-concept Phase I/II trial of a cancer drug developed by its subsidiary, Cerenis, which is being tested in refractory or relapsing acute myeloid leukemia (AML). (BioWorld International)

PARIS - BioAlliance Pharma SA completed its initial public offering on Eurolist Compartment C of the Euronext stock exchange in Paris, raising gross proceeds of some €30 million (US$35.9 million). (BioWorld International)

PARIS - BioAlliance Pharma SA completed its initial public offering on Eurolist Compartment C of the Euronext stock exchange in Paris, raising gross proceeds of some €30 million (US$35.9 million). (BioWorld International)